Elucidation of aggregation mechanism of Alzheimer's β-peptides and development of their aggregation inhibitors
Elucidation of aggregation mechanism of Alzheimer's β-peptides and development of their aggregation inhibitors
批准号:
13460048
负责人:
IRIE Kazuhiro
金额:
$9.66万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2003
中文摘要
阿尔茨海默病的神经病理学特征是淀粉样蛋白在编织实质和皮质血管中的进行性沉积。该沉积主要由40-和42-mer β-淀粉样肽(a - β40, a - β42)组成,具有神经毒性和聚集能力。家族性阿尔茨海默病的脑淀粉样血管病(CAA)与这些a - β肽编码区内的错义突变有关。为了阐明a β肽的聚集机制,我们以高纯度的形式合成了CAA中发现的a β40和a β42的所有变体,并检测了它们对PC12细胞的神经毒性和聚集能力。Aβ40突变体22和23位点的神经毒性均强于野生型Aβ40。22和23位的Aβ42突变体的神经毒性比对应的Aβ40突变体强50 ~ 200倍,这表明这些Aβ42突变体主要参与CAA的发病机制。特别是E…More 22q - a - β42(荷兰)和e22k - a - β42(意大利)广泛聚集,支持了荷兰和意大利患者诊断为遗传性脑出血合并淀粉样变的临床证据。相比之下,a21g (Flemish)突变除了a β突变体的物理化学性质外,还需要其他解释。FI-IR光谱表明,聚集增加了a - β肽的β-薄片含量。然而,转角也是聚集的关键二级结构,因为22和23位的残基更容易形成双残基β-转角,从而显著增强了聚集能力。为了鉴定对β-薄片形成重要的氨基酸残基,我们合成了一系列a - β42的脯氨酸取代突变体,并对它们的聚集能力和神经毒性进行了研究。只有E22P-Aβ42广泛聚集,神经毒性比野生型a β42强,说明15 ~ 21位和24 ~ 32位的残基参与了分子间β片的形成,22和23位的转位形成对a β肽的聚集和神经毒性起关键作用。这些发现为设计新的a - β肽聚集抑制剂奠定了基础。少
英文摘要
Alzheimer's disease is neuropathologically characterized by the progressive deposition of amyloid in the braid parenchyma and cortical blood vessels. This deposition mainly consists of 40-and 42-mer β-amyloid peptides (Aβ40, Aβ42) which show neurotoxicity and aggregative ability. Cerebral amyloid angiopathy (CAA) in familial Alzheimer's disease is related to missense mutations inside the coding region of these Aβpeptides. In order to clarify the aggregation mechanism of Aβpeptides, all of the variants of Aβ40 and Aβ42 found in CAA were synthesized in a highly pure form and examined for neurotoxicity in PC12 cells and aggregative ability.All of the Aβ40 mutants at positions 22 and 23 showed stronger neurotoxicity than wild-type Aβ40. Similar tendency was observed for Aβ42 mutants at positions 22 and 23 whose neurotoxicity was 50〜200 times stronger than that of the corresponding Aβ40 mutants, indicating that these Aβ42 mutants are mainly involved in the pathogenesis of CAA. Especially, E … More 22Q-Aβ42 (Dutch) and E22K-Aβ42 (Italian) aggregated extensively, supporting the clinical evidence that Dutch and Italian patients are diagnosed as hereditary cerebral hemorrhage with amyloidosis. In contrast, A21 G (Flemish) mutation needs alternative explanation with the exception of physicochemical properties of Aβmutants. The FI-IR spectra suggested that aggregation increases theβ-sheet contents of the Aβpeptides. However, turn was also a critical secondary structure for aggregation since residues at positions 22 and 23 that preferably form two-residue β-turn significantly enhanced the aggregative ability.To identify amino acid residues that are important for the β-sheet formation, a series of proline-substituted mutants of Aβ42 was synthesized and their aggregative ability and neurotoxicity were investigated. Only E22P-Aβ42 extensively aggregated with stronger neurotoxicity than wild-type Aβ42, suggesting that the residues at positions 15〜21 and 24〜32 are involved in the intermolecular β-sheet formation, and that turn formation at positions 22 and 23 plays a crucial role in the aggregation and neurotoxicity of Aβpeptides. These findings become a basis for designing new aggregation inhibitors of Aβpeptides. Less
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Kazuma Murakami: "Neurotoxicity and physicochemical properties of Aβ mutant peptides from cerebral amyloid angiopathy"The Journal of Biological Chemistry. 278・46. 46179-46187 (2003)
Kazuma Murakami:“脑淀粉样血管病的 Aβ 突变肽的神经毒性和理化特性”生物化学杂志 278・46(2003)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kazuma Murakami, Kazuhiro Irie et al.: "Synthesis, aggregation, neurotoxicity, and secondary structure of various Aβ1-42 mutants of familial Alzheimer's disease at positions 21-23"Biochem.Biophys.Res.Commun.. 294 (1). 5-10 (2002)
Kazuma Murakami、Kazuhiro Irie 等人:“家族性阿尔茨海默氏病 21-23 位的各种 Aβ1-42 突变体的合成、聚集、神经毒性和二级结构”Biochem.Biophys.Res.Commun. 294 (1)。 -10 (2002)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kazuma Murakami: "Synthesis, aggregation, neurotoxicity, and secondary structure of various β1-42 mutants of familial Alzheimer's disease at positions 21-23"Biochemical and Biophysical Research Communications. 294・1. 5-10 (2002)
Kazuma Murakami:“家族性阿尔茨海默病的各种β1-42突变体在位置21-23的合成、聚集、神经毒性和二级结构”《生物化学和生物物理研究通讯》294·1(2002)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kazuma Murakami: "Synthesis, aggregation, neurotoxicity, and secondary structure of various Aβ1-42 mutants of familial Alzheimer's disease at positions 21-23"Biochemical and Biophysical Research Communications. 294・1. 5-10 (2002)
Kazuma Murakami:“家族性阿尔茨海默氏病的各种 Aβ1-42 突变体在位置 21-23 的合成、聚集、神经毒性和二级结构”《生物化学和生物物理研究通讯》294·1(2002)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Akira Morimoto, Kazuhiro Irie et al.: "Aggregation and neurotoxicity of mutant amyloid β (Aβ) peptides with proline replacement: importance of turn formation at positions 22 and 23"Biochem.Biophys.Res.Commun.. 295 (2). 306-311 (2002)
Akira Morimoto、Kazuhiro Irie 等人:“脯氨酸取代的突变型淀粉样蛋白 β (Aβ) 肽的聚集和神经毒性:第 22 和 23 位转角形成的重要性”Biochem.Biophys.Res.Commun. 295 (2)。 -311 (2002)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 8 条
Search for novel PKC ligands as therapeutic seeds for intractable diseases
-
批准号:23658100
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.41万
-
财政年份:2011
-
负责人:IRIE Kazuhiro
-
依托单位:
Development of medicinal seeds for Alzheimer's disease based on the structural analysis of toxic oligomers of amyloid beta
-
批准号:21248015
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$29.45万
-
财政年份:2009
-
负责人:IRIE Kazuhiro
-
依托单位:
Development of antibodies and aggregation inhibitors for amyloid β peptides based on the new aggregation model
-
批准号:18208011
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$24.29万
-
财政年份:2006
-
负责人:IRIE Kazuhiro
-
依托单位:
Synthesis and characterization of the regulatory domains of protein kinase C
-
批准号:11660109
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.3万
-
财政年份:1999
-
负责人:IRIE Kazuhiro
-
依托单位:
Synthesis and PKC binding of conformationally restricted indolactams by aza-Claisen rearrangement
-
批准号:08660137
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.28万
-
财政年份:1996
-
负责人:IRIE Kazuhiro
-
依托单位:
国内基金
海外基金
登录
查看更多内容
FBXO42 经 Ube2m-Rbx1 轴促进 STAT3 介导的巨噬细胞线粒体自噬抗动脉粥样硬化的机制研究
-
批准号:ZCLQN26H0201
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:陈凌燕
-
依托单位:
基于CsDof16-CLE42模块的茶树氮高效育种靶点挖掘与机制研究
-
批准号:2026JJ80722
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:费雁泉
-
依托单位:
Cdc42通过抑制GSK-3β激酶活性介导YAP/TAZ异常激活在骨关节炎滑膜纤维化中的作用机制研究
-
批准号:2026JJ81824
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:吴克
-
依托单位:
小G蛋白Cdc42激活mTOR信号通路引发线粒体功能障碍:癌痛吗啡耐受机制的新视角
-
批准号:2026JJ81115
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李晴
-
依托单位:
磷酸化激活的USP42通过RPS3诱导缺血性脑卒中小胶质细胞糖酵解和M1极化的机制研究
-
批准号:2026JJ80170
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:周弟弥
-
依托单位:
戈米辛D精准靶向PDGFRβ活性位点Phe136调控CDC42分泌的抗肝纤维化机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:王蓉
-
依托单位:
泛素特异性蛋白酶42介导的Notch-铁死亡通路在胶质瘤干细胞干性维持和替莫唑胺治疗抵抗中的作用和机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:桑友洲
-
依托单位:
外泌体circ0060467介导CDC42蛋白SUMO化修饰促进肝癌转移和耐药的机制研究
-
批准号:2025JJ80098
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:朱红波
-
依托单位:
针对 RhoAY42C 突变的基因组稳定型胃癌靶
向 ICAM1 位点的抗体偶联药物研究
-
批准号:TGY24H160089
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:陈佳辉
-
依托单位:
cdc42通过调控血管内皮细胞的增殖修复和旁分泌机制来介导系统性硬化症相关肺纤维化的发生发展
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:胡国栋
-
依托单位: